Once enough people receive effective vaccines against the novel coronavirus, experts say, the end of the pandemic may be in sight. But a new poll of older adults — one of the highest-priority groups for vaccination — suggests an uphill climb lies ahead to reach that goal. In all, 58% of adults aged 50 to […]
Surging COVID-19 cases across the U.S. could hold medical procedures back for the rest of the year, according to a new report from UBS analysts. If the UBS analysts’ prediction proves accurate, medical device companies could face a challenging environment for the rest of the year, even as they provide the technology, tests and supplies […]
UBS Financial Services released a report detailing how it expects medtech procedures to potentially keep dipping during the COVID-19 pandemic. The report highlighted a quicker-than-expected recovery in the second quarter after U.S. hospitals began canceling, delaying and deferring elective procedures in late March as the pandemic took hold. However, UBS still expects third-quarter medical procedures […]
After deciding this week that its CEO needs to be based in Eagan, Minn., and with chief executive Chris von Jako unwilling to relocate his family, Dynatronics (NSDQ:DYNT) promoted COO Brian Baker to the corner office, effective August 28. “After thoughtful consideration, the board of directors determined that the company’s CEO needs to be based in […]
A Texas doctor accused of unnecessary stenting has slipped three of four trials against him with his license to practice in the Lone Star State intact.
Dr. Samuel DeMaio, accused last year of standard-of-care violations related to nine patients who allegedly received un-needed stents, angiograms and ICD implants, had pushed for a trial after mediation efforts with the Texas Medical Board collapsed.
Abiomed Inc.’s (NSDQ:ABMD recent good fortune may make it a prime acquisition target, according to Wall Street analysts.
Boston Scientific Corp. (NYSE:BSX) garnered two upgrades and one downgrade from analysts this week, creating a roller-coaster effect in stock prices for the medical device giant.
The company’s stock has been closing at higher and higher values all week, but slid nearly 4 percent in midday trading Friday after an analyst at wealth management service UBS downgraded the stock from buy to neutral.
Wall Street analyst Rajeev Jashnani said the stock isn’t likely to trade higher until BSX can report sustained revenue.